Purdue Targets Palladone Phased Launch Start For First Half Of 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
For the first 18 months of launch, Purdue will limit promotion to experienced opioid-prescribing physicians to assess whether the appropriate patients are receiving extended-release hydromorphone.